The earnings are scheduled for June 20, and that will determine the short term course for the stock. The movement from $1 to $3 has been breathtaking. Within 6-7 months, the stock has tripled and the momentum is not subsiding. The volumes have been great and it is defying the words of caution from the analysts. Caution is being called mainly because the rise has factored most of the turnaround positives in the short term. It is appearing a little stretched on fundamentals if compared with peers. This is mainly because the stock has already moved exponentially. While the long term story may remain bullish, there may be some consolidation after the upcoming earnings. In fact, in case of negative surprises, there may be a correction also. Further, the revenues fell by ~10% in the last earnings because the company chose to concentrate only on the more profitable products. While this strategy may work up to a point, it is important to maintain a minimum level of sales to support the fixed cost of the establishment. So there is not much room for decline in sales this time around. It is trying to get successful products from companies like Empowered Products to bolster sales. Even offerings from other companies may help the front end sales. A new ingredient, Nicotinamide Riboside has been launched by Chromadex Corporation (CDXC) which is being promoted as a wonder vitamin. Other companies are also bringing out innovative products from time to time. Further, RAD definitely needs to deliver on the net income front in the earnings. Any slippages there could be a negative for the stock. However, it is also possible that it delvers a positive surprise and goes much higher than the current levels. So one needs to play the earnings carefully depending on individual risk appetite. One needs to be a little careful.
AI
Market Data 
Markets 
